Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study

Abstract

Introduction Considering limited global access to affordable insulin, we evaluated insulin access in public and private health sectors in Bengaluru, India. Methods Employing modified WHO/HAI methodology, we used mixed-methods analysis to study insulin access and factors influencing insulin supply and demand in Bengaluru in December 2017. We assessed insulin availability, price and affordability in a representative sample of 5 public-sector hospitals, 5 private-sector hospitals and 30 retail pharmacies. We obtained insulin price data from websites of government Jan Aushadhi scheme (JAS) and four online private-sector retail pharmacies. We interviewed wholesalers in April 2018 to understand insulin market dynamics. Results Mean availability of insulins on India’s 2015 Essential Medicine List was 66.7% in the public sector, lower than private-sector retail (76.1%) and hospital pharmacies (93.3%). Among private retailers, mean availability was higher among chain (96.7%) than independent pharmacies (68.3%). Non-Indian companies supplied 67.3% products in both sectors. 79.1% products were manufactured in India, of which 60% were marketed by non-Indian companies. In private retail pharmacies, median consumer prices of human insulin cartridges and pens were 2.5 and 3.6 times, respectively, that of human insulin vials. Analogues depending on delivery device were twice as expensive as human insulin. Human insulin vials were 18.3% less expensive in JAS pharmacies than private retail pharmacies. The lowest paid unskilled worker would pay 1.4 to 9.3 days’ wages for a month’s supply, depending on insulin type and health sector. Wholesaler interviews suggest that challenges constraining patient insulin access include limited market competition, physicians' preference for non-Indian insulins, and the ongoing transition from human to analogue insulin. Rising popularity of online and chain pharmacies may influence insulin access. Conclusion Insulin availability in Bengaluru’s public sector falls short of WHO’s 80% target. Insulin remains unaffordable in both private and public sectors. To improve insulin availability and affordability, government should streamline insulin procurement and supply chains at different levels, mandate biosimilar prescribing, educate physicians to pursue evidence-based prescribing, and empower pharmacists with brand substitution. Patients must be encouraged to shop around for lower prices from subsidized schemes like JAS. While non-Indian companies dominate Bengaluru’s insulin market, rising market competition from Indian companies may improve access.

Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India

“…As noted earlier, GSDPs offered a better mix, that is, availability similar to that of private retail pharmacies but with better affordability (lower prices). Despite conspicuous affordability, popularity of Jan Aushadhi is low possibly because of poor governmental support, inadequate campaigning, inferior supply chain and negative perceptions about the quality of low-priced generics [41]. A systematic review reported that a significant proportion of both physicians and pharmacists consider generic medicines inferior, despite 35 of 38 trials demonstrating clinical equivalence between OB and generic versions of multiple CVD medicines [42,43].…”

India’s latest essential medicines list: gaps, strengths and opportunities in evidence-based decision-making

“…The WHO included insulin analogues citing ‘lower incidence of symptomatic and nocturnal hypoglycaemia’ while acknowledging that the clinical benefits of analogues over human form are too small to justify the large price difference 11. This is more difficult to justify in countries with limited healthcare resources, especially India, where even human insulin continues to be unaffordable and poorly available despite being ‘essential’ since 1996 12…”

Genesis of People’s Medicine Centre (PMC) for popularisation of generic medicine: A critical qualitative inquiry

“…One of the causes of low compliance to psychiatric medication is the high cost of the drugs, which many people from lower socioeconomic classes cannot afford, particularly when they are needed for an extended period. 4 Therefore, it is crucial to dispense high-quality medicines in sufficient quantities and at an affordable price to encourage treatment adherence. 5 A study on private pharmacies as healthcare providers in Odisha find that a large population prefer to use private pharmacies as compared to other public health providers, thus increasing their Out-of-Pocket (OOP) expenses.…”